Melatonin decreases cocaine-induced locomotor sensitization and cocaine-conditioned place preference in rats.


Journal

Journal of psychiatric research
ISSN: 1879-1379
Titre abrégé: J Psychiatr Res
Pays: England
ID NLM: 0376331

Informations de publication

Date de publication:
01 2021
Historique:
received: 14 04 2020
revised: 11 09 2020
accepted: 25 09 2020
pubmed: 21 10 2020
medline: 15 5 2021
entrez: 20 10 2020
Statut: ppublish

Résumé

Melatonin is a hormone that produces behavioral, pharmacological, and physiological effects through the activation of MT1 and MT2 melatonin receptors. Melatonin receptors participate in the modulation of the reinforcing effects of cocaine. Some studies report that dosing of melatonin decreases cocaine-induced locomotor activity and cocaine self-administration and that luzindole, an MT1, and MT2 melatonin receptor antagonist, blocks the melatonin-dependent decrease in cocaine-induced locomotor activity. The objective of this study was to evaluate the effect of acute or chronic dosing of melatonin on the induction and expression of cocaine-induced locomotor sensitization and cocaine-CPP in rats. Male Wistar rats received cocaine during the induction and expression of locomotor sensitization. Melatonin was administered 30 min before cocaine. After each treatment, locomotor activity was recorded for 30 min. Additionally, dopamine levels were determined in the ventral striatum, the prefrontal cortex (PFc), and the ventral tegmental area (VTA) by HPLC in animals treated with melatonin and cocaine. Melatonin decreased cocaine-induced locomotor sensitization and intracellular dopamine levels, as well as cocaine-CPP. Luzindole blocked the melatonin-induced decrease in the expression of locomotor sensitization in rats. These data suggest that melatonin may be a useful therapeutic agent to reduce cocaine abuse; additionally, they suggest that MT1 and MT2 receptors could be therapeutic targets, useful for the treatment of drug abuse disorder.

Identifiants

pubmed: 33080430
pii: S0022-3956(20)30993-6
doi: 10.1016/j.jpsychires.2020.09.027
pii:
doi:

Substances chimiques

Receptor, Melatonin, MT2 0
Cocaine I5Y540LHVR
Melatonin JL5DK93RCL

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

97-110

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Susana Barbosa-Méndez (S)

Subdirección de Investigaciones Clínicas, Laboratorio de Neurofarmacología Conductual, Microcirugía y Terapéutica Experimental, Ciudad de México, 14370, Mexico.

Gilberto Pérez-Sánchez (G)

Dirección de Neurociencias, Laboratorio de Psicoinmunología, Instituto Nacional de Psiquiatría, Ciudad de México, 14370, Mexico.

Enrique Becerril-Villanueva (E)

Dirección de Neurociencias, Laboratorio de Psicoinmunología, Instituto Nacional de Psiquiatría, Ciudad de México, 14370, Mexico.

Alberto Salazar-Juárez (A)

Subdirección de Investigaciones Clínicas, Laboratorio de Neurofarmacología Conductual, Microcirugía y Terapéutica Experimental, Ciudad de México, 14370, Mexico. Electronic address: azazel_vamp@yahoo.com.mx.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH